sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Patient Information Leaflet last updated on the eMC: 05/01/2011
PIL Suprefact Injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05/01/2011 and displayed until Current
Reasons for adding or updating:
  • Change to storage instructions
Updated on 01/12/2009 and displayed until 05/01/2011
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Changes to therapeutic indications
Updated on 01/08/2008 and displayed until 01/12/2009
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 16/08/2006 and displayed until 01/08/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 06/06/2003 and displayed until 16/08/2006
Reasons for adding or updating:
  • Update to PIL

Active Ingredients/Generics

 
   buserelin acetate